These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22777740)

  • 1. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
    Carr BI; Cavallini A; Lippolis C; D'Alessandro R; Messa C; Refolo MG; Tafaro A
    J Cell Physiol; 2013 Feb; 228(2):292-7. PubMed ID: 22777740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility of regorafenib effects in hepatocellular carcinoma cells.
    D'Alessandro R; Refolo MG; Lippolis C; Messa C; Cavallini A; Rossi R; Resta L; Di Carlo A; Carr BI
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):869-77. PubMed ID: 23959464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G; Wang M; Hyslop T; Wang Z; Carr BI
    Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy.
    Han R; Li S
    Pharmazie; 2018 Apr; 73(4):218-222. PubMed ID: 29609689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
    Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
    Carr BI; D'Alessandro R; Refolo MG; Iacovazzi PA; Lippolis C; Messa C; Cavallini A; Correale M; Di Carlo A
    J Cell Physiol; 2013 Jun; 228(6):1344-50. PubMed ID: 23169148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
    Tsai JJ; Pan PJ; Hsu FT
    Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
    Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
    Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
    Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.